Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of “Buy” from Brokerages

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have received a consensus recommendation of “Buy” from the thirteen research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $108.75.

MNPR has been the topic of several research analyst reports. Chardan Capital reiterated a “buy” rating and set a $100.00 price target on shares of Monopar Therapeutics in a research report on Monday, March 30th. UBS Group set a $105.00 price objective on shares of Monopar Therapeutics in a report on Monday, June 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Tuesday, April 21st. Piper Sandler set a $105.00 target price on Monopar Therapeutics in a research report on Tuesday, June 2nd. Finally, Wall Street Zen upgraded Monopar Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Bank of America Corp DE boosted its stake in Monopar Therapeutics by 838.2% during the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after acquiring an additional 53,336 shares in the last quarter. ADAR1 Capital Management LLC lifted its holdings in shares of Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after purchasing an additional 30,370 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Monopar Therapeutics in the 1st quarter worth approximately $250,000. Siren L.L.C. boosted its position in shares of Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after purchasing an additional 57,820 shares in the last quarter. Finally, Sei Investments Co. grew its stake in shares of Monopar Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after buying an additional 656 shares during the last quarter. 1.83% of the stock is currently owned by institutional investors.

Monopar Therapeutics Stock Performance

MNPR opened at $95.22 on Friday. Monopar Therapeutics has a 52-week low of $29.18 and a 52-week high of $105.00. The stock has a market capitalization of $637.97 million, a PE ratio of -50.12 and a beta of 1.46. The stock’s 50 day moving average price is $68.04 and its 200-day moving average price is $63.09.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.41. Research analysts forecast that Monopar Therapeutics will post -2.82 EPS for the current fiscal year.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.